Clinicopathologic factors such as age, tumor size, stage, nodal status, hormone receptor (HR) status (estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)) are widely considered in risk-adapted therapy decisions and as prognostic indicators for breast cancer progression [6, 7]. The gene discussed is ERBB2; the disease is neoplasm.